Hypoxia-activated prodrugs as antitumour agents: strategies for maximizing tumour cell killing - PubMed (original) (raw)
Hypoxia-activated prodrugs as antitumour agents: strategies for maximizing tumour cell killing
W R Wilson et al. Clin Exp Pharmacol Physiol. 1995 Nov.
Abstract
1. Hypoxia arises in solid tumour because of inefficient blood supply. While hypoxic cells are resistant to radiotherapy and probably to many chemotherapeutic drugs they can, in principle, be turned to advantage through the development of hypoxia-activated cytotoxic drugs (bioreductive drugs). 2. Three general approaches to exploiting tumour hypoxia are discussed. The first relies on fluctuating blood flow in tumours and the consequent cycling of cells through the hypoxic compartment. The second incorporates a prodrug approach in which drug activation gives rise to cytotoxic metabolites which diffuse out of hypoxic zones. The third utilizes selective inhibitors of tumour blood flow to induce additional hypoxia and thus enhance bioreductive drug activation. 3. The latter two approaches are illustrated by recent studies with the dinitrobenzamide nitrogen mustard class of bioreductive drugs and their combination with the tumour blood flow inhibitor 5,6-dimethylxanthenone-4-acetic acid.
Similar articles
- Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Lash CJ, et al. Br J Cancer. 1998 Aug;78(4):439-45. doi: 10.1038/bjc.1998.512. Br J Cancer. 1998. PMID: 9716024 Free PMC article. - Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5.
Kestell P, Pruijn FB, Siim BG, Palmer BD, Wilson WR. Kestell P, et al. Cancer Chemother Pharmacol. 2000;46(5):365-74. doi: 10.1007/s002800000165. Cancer Chemother Pharmacol. 2000. PMID: 11127940 - Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
Guise CP, Wang AT, Theil A, Bridewell DJ, Wilson WR, Patterson AV. Guise CP, et al. Biochem Pharmacol. 2007 Sep 15;74(6):810-20. doi: 10.1016/j.bcp.2007.06.014. Epub 2007 Jun 17. Biochem Pharmacol. 2007. PMID: 17645874 - Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).
Denny WA, Wilson WR. Denny WA, et al. Cancer Metastasis Rev. 1993 Jun;12(2):135-51. doi: 10.1007/BF00689806. Cancer Metastasis Rev. 1993. PMID: 8375017 Review. - Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
Denny WA. Denny WA. Future Oncol. 2010 Mar;6(3):419-28. doi: 10.2217/fon.10.1. Future Oncol. 2010. PMID: 20222798 Review.
Cited by
- Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Lash CJ, et al. Br J Cancer. 1998 Aug;78(4):439-45. doi: 10.1038/bjc.1998.512. Br J Cancer. 1998. PMID: 9716024 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources